Protocol

ANGIO1: Phase I Study of Bevacizumab and Sorafenib Combined with Low Dose Cyclophosphamide in Patients with Refractory Solid Tumors and Leukemia

Diseases

Leukemias / Lymphomas : Recurrent or refractory solid tumors and leukemias

Description

This research is being done to find new and more effective treatments against childhood cancers. The children enrolled in this study have a solid tumor or leukemia that has either come back (relapsed) or did not respond to treatment (refractory) or there is no therapy known to be effective.

The purpose of this study is to find the largest dose of sorafenib and bevacizumab in combination with low dose cyclophosphamide that can be given safely to children and young adults with solid tumors and leukemia. This study combines three drugs that are thought to work on tumors by affecting the blood vessels in the tumor. We have recently identified a dose of the combination of these drugs that appears to be safe to use in children with solid tumors. We are now treating children with relapsed or refractory solid tumor or leukemia at these doses to better understand the side effects of these drugs when they are given together.


Objectives


Eligibility

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).


Contact

Fariba Navid, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only: protocolinfo@stjude.org
For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.